News | May 10, 2011

MRI Contrast Agent Guidelines Help Prevent Debilitating Disorder

May 10, 2011 – A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in magnetic resonance imaging (MRI) exams, according to a study published in the July issue of Radiology.

Within the past five years, use of gadolinium-based contrast agents (GBCA) has been linked to the development of nephrogenic systemic fibrosis (NSF), a rare disorder mainly affecting patients with severe kidney disease. But since 2008, restrictive GBCA administration guidelines implemented by Massachusetts General Hospital have proven effective in preventing NSF.

“It is important for the public to know that gadolinium products are safe for most patients and the risk of NSF should not deter them from GBCA-enhanced exams, such as MRIs,” said the study’s lead author Hani H. Abujudeh, M.D., MBA, associate professor of radiology at Harvard Medical School in Boston.

NSF is characterized by widespread tissue fibrosis. Patients with NSF experience an increase of collagen in the tissues, causing thickening and hardening of the skin of the extremities, and often resulting in immobility and tightening or deformity of the joints. NSF can develop rapidly and may result in patients becoming wheelchair-bound within just a few weeks. In some cases, there is involvement of other tissues, including the lungs, heart, diaphragm, esophagus and skeletal muscle.

Massachusetts General Hospital began implementing restrictive GBCA guidelines in May 2007 in order to protect patients from potentially developing NSF. The guidelines require that a blood test be done on patients over age 60 or at risk for kidney disease. The blood test measures how well the kidneys are doing. That number is then converted via a formula to estimate the glomerular filtration rate (eGFR), which measures the rate of fluid flow through the kidneys. The guidelines stipulate a maximum GBCA dose of 20 mL for patients with a low eGFR (below 60 mL/min/m2). GBCA should not be administered at all to patients currently undergoing dialysis treatment or with a very low eGFR (below 30 mL/min/m2).

For the study, Abujudeh and colleagues reviewed the hospital’s medical records during the pre-guideline and transition period (January 2002 through December 2007) and the post-adoption period (January 2008 to March 2010). Prior to adoption of the guidelines and during the transition period, 113,120 contrast-enhanced MRI exams were performed, and 34 cases of NSF were subsequently identified. During the post-guideline period, 52,954 contrast-enhanced MRIs were performed with no new cases of NSF identified.

“The findings prove that these guidelines are effective,” Abujudeh said, “and that strategies can be put into practice to ensure patient safety.”

For more information: www.rsna.org

Related Content

MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
FDA Clears Siemens Magnetom Terra 7T MRI Device

The FDA has cleared the Siemens Magnetom Terra as the first 7T MRI system in the U.S. to gain regulatory approval.

Technology | Magnetic Resonance Imaging (MRI)| October 12, 2017
The U.S. Food and Drug Administration (FDA) cleared the first 7 Tesla (7T) magnetic resonance imaging (MRI) device,...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI)| October 11, 2017
MR Solutions took their cryogen-free preclinical multimodality magnetic resonance imaging (MRI) solutions on tour in...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI)| September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
GE Healthcxare Signa Pioneer MAGIC six contrasts in one scan software by SyntheticMR.

The MRI software enables several different contrasts to be obtained from one scan, shortening scan times.

Feature | Magnetic Resonance Imaging (MRI)| August 31, 2017
August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI.
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Overlay Init